Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move- (CSE: $SLNG.C) (NYSE: $CGC) (CSE: $TER.C) (CSE: $MYM.C) (CSE: $CURA.C)
Delta, Kelowna, BC –May 2, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at
Today’s podcast overview/transcript:
Good morning and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast I focus on a few early announcements from some interesting companies.
SLANG Worldwide Inc. (CSE: SLNG), a leading global cannabis consumer packaged goods company with a robust portfolio of renowned brands distributed across 2,600 stores in 11 US states, announced the establishment of its new wellness-focused business division, SLANG Health and Wellness. The new business unit will develop and market a portfolio of plant-based cannabidiol products that will be distributed in partnership with Greenlane Holdings, Inc. (NASDAQ: GNLN) through their extensive distribution network.
"Consumers are increasingly interested in natural plant-based wellness products, and we've only scratched the surface of the opportunity within cannabinoid-supported wellness," said SLANG CEO Peter Miller. "Health and Wellness represents a new market segment for SLANG and is a natural extension for our portfolio of top selling products across the US and internationally. We expect early sales to be supported by the brand awareness and customer loyalty that we've developed within our existing portfolio over many years of innovation and
consumer focus."
SLANG Health and Wellness products will target a rapidly expanding and promising consumer market that is expected to grow from US$591 million in 2018 to US$22 billion by 2022, according to The Brightfield Group. The Company will initially focus on extending SLANG's existing industry leading portfolio of THC-dominant products into the CBD space and will immediately launch sales of the Company's best-selling O.penVAPE Reserve brand, to be sold as a half gram hemp-based CBD cartridge.
Canopy Growth Corporation(TSX: WEED) (NYSE: CGC) announced that it has acquired German-based, Bionorica SE-founded C3 Cannabinoid Compound Company in a transformative deal that will see established single cannabinoid medicines brought together with the world's leading full-spectrum medical cannabis offering.
The all cash-acquisition for €225.9 million (CDN $342.9 million) furthers Canopy Growth's expansion into European markets with prescription medicines and gives the Company immediate access to a wealth of knowledge and intellectual property that C3 has developed in its nearly 20 years of research and development into synthetic and natural cannabis medical products.
C3's primary medicinal offering is dronabinol, a pure chemical compound with standardized concentrations of tetrahydrocannabinol (THC), one of the active ingredients found in cannabis plants that is responsible for various pharmacological effects. Dronabinol is available in Austria, Denmark, and Germany for nausea and vomiting refractory to conventional treatment in oncology and palliative care, and for cancer pain. In Germany, dronabinol can be prescribed for any type of chronic pain and for any condition in palliative care. C3 has a total of five medicines in the market and its commercial operations generated €27.1 million (CDN $41.5 million) in 2018.
The acquisition will allow Canopy Growth to further empower European physicians with the knowledge and therapies drawn from the full range of synthetic to naturally-derived cannabinoid-based medicines. Adding dronabinol to Canopy Growth's product offering in Europe and potentially other key markets will allow the Company's medical division, Spectrum Cannabis, to present an expanded, medically validated suite of cannabinoid therapies to the benefit of healthcare professionals and patients. Furthermore, C3's infrastructure including production, distribution, and sales & marketing significantly adds to the Spectrum Cannabis footprint in Europe, including an expanding product line and additional reach into pharmacy and medical specialists' networks.
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) today announced that its manufacturing facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice certificate in accordance with the rules governing medicinal products in the European Union.
The EU GMP certification was awarded by the responsible agency, Arzneimittelbehörde, in North Rhine-Westphalia, Germany. Additionally, the Company has entered a comprehensive sales and distribution agreement with iuvo Therapeutics GmbH, a German pharmaceutical wholesaler with a cannabis-specific import and distribution license. TerrAscend expects to begin distribution through iuvo this quarter.
"Just five months ago, TerrAscend became the first North American Operator (NAO), with scale operations in both Canada and the US. Upon commencement of shipments this quarter, through our partner iuvo in Germany, TerrAscend will be the first and only global cannabis operator with sales in the three largest markets in the world," said Dr. Michael Nashat, CEO of TerrAscend. "We will continue to expand our sales footprint going forward and will share news of these milestones as we achieve them."
MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) announced that the Company has acquired 50% of BioHemp Naturals ("BioHemp"), a licensed hemp cultivator in the business of cultivating and distributing CBD-rich hemp biomass to licensed producers in Canada. BioHemp co-founder, Len Atkinson, will join the MYM management team as Global Hemp Project Manager.
BioHemp's founder has been growing hemp since 2015 and developed unique harvesting methods and standard operating procedures which meet all Health Canada testing requirements for hemp. BioHemp is expanding its hemp operations to cultivate 450 acres this 2019 season with plans to expand to 3,000 acres of certified organic hemp in 2020. Forecasted revenues based on the sale of biomass for the 2019 grow season are expected to exceed $30 million with 2020 grow season $225 million.The partnership will allow BioHemp to toll-process the hemp flower through MYM's planned extraction plant which would significantly increase revenues for both seasons.
"Acquiring 50% of BioHemp Naturals and engaging Mr. Atkinson as MYM's Global Hemp Project Manager is a huge win for MYM and our stated goal to become global CBD-rich hemp cultivators, extractors, and distributors," said Howard Steinberg, CEO of MYM. "The addition of BioHemp Naturals adds over 3,000 acres of cultivation to the company which is expected to significantly increase future revenues of MYM."
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) , a leading vertically integrated cannabis operator in the United States, unveiled its new Arizona initiative with the Veterans Cannabis Project (VCP), an organization that advocates for legal and supported access of medical cannabis for veterans through the Department of Veterans Affairs. Patients at Curaleaf's five Arizona locations can purchase a custom-designed "Veterans Cannabis Project" pre-roll product, with a portion of all proceeds benefiting the VCP. Each box includes five pre-rolls and will be available for $16.
Veterans and concerned citizens also participated in the launch of a nationwide petition and grassroots campaign supporting medical cannabis. The campaign urges Congress to authorize access, provide protections, and require research into medical cannabis. Additionally, it calls for the Department of Veterans Affairs to give veterans access to the cannabis they overwhelmingly want and deserve. The petition can be accessed here: https://www.vetscp.org/act.
To celebrate the launch, local veterans visited Curaleaf's Midtown location to hear Dr. Sue Sisley, an Arizona scientist who conducted the first FDA-approved study of cannabis for PTSD in veterans, speak about her recent research. Steve Cottrell, President of Curaleaf Arizona, and Doug Distaso, Executive Director of VCP, also spoke about the new initiative aimed at raising awareness and support around veterans' access.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
